Filing Details
- Accession Number:
- 0000899243-18-019753
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-11 17:05:32
- Reporting Period:
- 2018-07-09
- Accepted Time:
- 2018-07-11 17:05:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1631574 | Wave Life Sciences Ltd. | WVE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1657709 | Chris Francis | C/O Wave Life Sciences Ltd., 733 Concord Ave. Cambridge MA 02138 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2018-07-09 | 23,900 | $2.48 | 45,977 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2018-07-09 | 23,900 | $37.25 | 22,077 | No | 4 | S | Direct | |
| Ordinary Shares | Acquisiton | 2018-07-09 | 596 | $2.48 | 22,673 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2018-07-09 | 596 | $38.22 | 22,077 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Share Option (right to buy) | Disposition | 2018-07-09 | 24,496 | $0.00 | 24,496 | $2.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 52,572 | 2025-03-10 | No | 4 | M | Direct |
Footnotes
- The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $37.00 to $37.975 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.10 to $38.25 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
